Valigen US Inc

WWWWWWWWWW

Valigen US Inc
Profile last edited on: 12/4/2007

combining genomics and chimeroplasty to achieve seed and crop improvements without introducing exogenous genetic material into the seed.
Year Founded
1994
First SBIR Year
2001
Latest SBIR Award
2001
Program Status
Inactive

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

350 Carter Road
Princeton, NJ 08540
   (215) 504-4444
   N/A
   www.valigen.net
Multiple Locations:   
Congressional District:   12
County:   Mercer

Public Profile

ValiGen US was the US component of a private firms was created in April 2000 through the merger of Kimeragen Inc. of Newtown, PA and Valigene, a Paris-based genomics company. Kimeragen had been founded in 1994 to commercialize chimeraplasty, a gene correction technology designed to develop new treatments for genetic diseases and to identify new drug candidates. The company's functional genomics activities were based in Paris; research on biotech applications in plants and industrial products and bioengineered food products was conducted is San Diego. ValiGen also had offices in Berlin, Germany, where the company is involved in developing population databases, which patients could use for genetic health-risk assessments and drug companies can use to identify potential targets for therapies to treat genetic diseases. Valigen's CEO was Douglas Watson, the former head of Novartis; th scientific advisory boared that included J. Craig Venter and Nobel laureate Hamilton Smith of Celera Genomics. In October 2001, Watson resigned; ValiGen closed its Princeton, New Jersey, laboratory, the site of nearly all its chimeraplasty research. The company was undergoing bankruptcy reorganization in France; the license for chimeraplasty was placed with a small company in San Diego, California, to pursue the technology in plants.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
N/A
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
: N/A
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Phase I amount Phase II amount Total Dollars Phase I title Nid
2001 1 Army 118,173 0 $118,173 Novel Gene Repair Technology to Generate Serum Carboxylesterase Deficient Mice 8744

People

  Douglas Watson -- President

  Bryan A Roecklein --

SBIR firms in the news